Clostridium difficile-associated disease acquired in the cardiothoracic intensive care unit

Journal of Cardiothoracic and Vascular Anesthesia
Saif A MusaT M Rahman

Abstract

To determine the prevalence, severity, and outcome associated with Clostridium difficile-associated disease (CDAD) acquired while in the cardiothoracic intensive care unit (CTICU). A 5-year retrospective study. The CTICU. All CTICU patients with a positive C difficile stool toxin assay 48 hours after admission. None. The results of all CTICU patients with a positive C difficile stool toxin assay were obtained from the Microbiology Department. Each patient's medical notes and charts then were reviewed in turn. A total of 27 of 5,199 (0.5%) CTICU patients acquired CDAD. The median age was 74 years (IQR 68-77), and 17 (63%) patients were male. There were 21 (78%) surgical patients; 13 (62%) were elective admissions. The most frequent diagnosis on admission was valvular heart disease (10 [37%] patients). Sixteen (59%) patients underwent coronary artery bypass graft (CABG) surgery and/or valvular heart surgery. The median interval between CTICU admission and CDAD diagnosis was 10 days (IQR 5-18). Previously identified risk factors for ICU-acquired CDAD included age >65 years (23), antibiotic use (26), and medical device requirements (27). At the time of diagnosis, 14 (52%) patients had moderate CDAD. After treatment initiation, 8 (3...Continue Reading

References

Feb 1, 1991·American Journal of Infection Control·T G EmoriR P Gaynes
Apr 30, 2004·The Journal of Infectious Diseases·Lennox K ArchibaldWilliam R Jarvis
Feb 1, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Steven J LawrenceLinda M Mundy
Mar 27, 2007·The Annals of Thoracic Surgery·Traves CrabtreeRalph J Damiano
Sep 12, 2007·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Patricia MuñozEmilio Bouza
Oct 11, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Mathieu BeaulieuJean Lachaine
Feb 7, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dale N GerdingRobert C Owens
Feb 12, 2008·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Luca Salvatore De SantoMaurizio Cotrufo
Mar 26, 2008·Critical Care Clinics·Daniel M Musher, Saima Aslam
Nov 4, 2008·The Lancet Infectious Diseases·Tim PlancheSanjeev Krishna
Feb 17, 2009·Journal of Cardiothoracic and Vascular Anesthesia·Teresa Inkster
Aug 4, 2009·BMC Medicine·Mary A M RogersBrahmajee K Nallamothu

❮ Previous
Next ❯

Citations

Dec 7, 2013·World Journal of Gastroenterology : WJG·Nagham KhanaferPhilippe Vanhems
Apr 2, 2013·The Journal of Thoracic and Cardiovascular Surgery·Brian T BatemanNiteesh K Choudhry
May 31, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mark H Wilcox
Nov 4, 2016·The American Journal of Gastroenterology·David M FaleckDaniel E Freedberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.